硕世生物高管自愿降薪，董事长年薪从1550万降至240万

Core Viewpoint - The IVD industry is facing significant challenges, leading to salary reductions among executives and a general trend of cost-cutting measures across companies in the sector [1][5][8]. Summary by Sections Company Actions - Executives at Shuoshi Bio have voluntarily reduced their salaries in response to ongoing economic pressures, with the chairman's salary cut by 50% and other executives seeing reductions of up to 40% [3][5]. - The company has implemented various cost control measures, resulting in decreased sales, management, and R&D expenses in the first half of 2025 [5][6]. Financial Performance - Shuoshi Bio reported a revenue of 1.76 billion yuan in the first half of 2025, a slight decline of 1.05% year-on-year, while net profit dropped by 86.35% to 39.93 million yuan [5][6]. - The company's revenue peaked at 5.535 billion yuan in 2022 but has since declined, with projections of 4.03 billion yuan in 2023 and 3.49 billion yuan in 2024 [5][6]. Industry Trends - The IVD industry has entered a downward cycle since peaking in 2022, with over 40 out of 60 listed companies reporting declines in both revenue and net profit in the first half of 2025 [8]. - Price reductions due to centralized procurement have significantly compressed profit margins, with some products seeing price drops of up to 92% [8][9]. Market Opportunities - Companies are increasingly looking to overseas markets for growth, with Shuoshi Bio planning to establish international marketing teams and diversify sales channels [9][10]. - Despite a 31.32% year-on-year increase in overseas revenue to 6.9342 million yuan, it still only represents 3.95% of total revenue [10].